2022
DOI: 10.3390/ijms23147513
|View full text |Cite
|
Sign up to set email alerts
|

Type 2 Transglutaminase in Coeliac Disease: A Key Player in Pathogenesis, Diagnosis and Therapy

Abstract: Type 2 transglutaminase (TG2) is the main autoantigen in coeliac disease (CD), a widespread inflammatory enteropathy caused by the ingestion of gluten-containing cereals in genetically predisposed individuals. As a consequence, serum antibodies to TG2 represent a very useful marker in CD diagnosis. However, TG2 is also an important player in CD pathogenesis, for its ability to deamidate some Gln residues of gluten peptides, which become more immunogenic in CD intestinal mucosa. Given the importance of TG2 enzy… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
5
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 22 publications
(10 citation statements)
references
References 133 publications
0
5
0
Order By: Relevance
“…Obstruction of sweat glands and hypohidrosis was reported for patients carrying mutations of TGM1 [38]. Considering the recent advances in the understanding, diagnosis and therapy of TGM-dependent diseases [39][40][41][42][43][44][45][46], it will be interesting to further explore the roles of TGMs in sweat glands and other skin appendages.…”
Section: Discussionmentioning
confidence: 99%
“…Obstruction of sweat glands and hypohidrosis was reported for patients carrying mutations of TGM1 [38]. Considering the recent advances in the understanding, diagnosis and therapy of TGM-dependent diseases [39][40][41][42][43][44][45][46], it will be interesting to further explore the roles of TGMs in sweat glands and other skin appendages.…”
Section: Discussionmentioning
confidence: 99%
“…This prevents gluten from reaching the lamina propria and stimulating the immune system ( Varma and Krishnareddy, 2022 ). Other proposed strategies aim at blocking immune response to gluten peptides by: • transglutaminase transglutaminase 2 (TG2) blockers preventing deamidation of gluten peptides and their efficient presentation to CD4 + T cells ( Paolella et al, 2022 ); • inhibiting epithelial damage driven by IL-15 with anti-IL15 antibodies or opposing the outgrowth of malignant IELs in type II refractory CD; • immunotherapy to restore gluten tolerance through stimulation-induced death of small intestinal epithelial cells and immune activation through the production of regulatory T cells ( Cerf-Bensussan and Schuppan, 2021 ; Varma and Krishnareddy, 2022 ). …”
Section: Celiac Disease Novel Therapiesmentioning
confidence: 99%
“…• transglutaminase transglutaminase 2 (TG2) blockers preventing deamidation of gluten peptides and their efficient presentation to CD4 + T cells ( Paolella et al, 2022 );…”
Section: Celiac Disease Novel Therapiesmentioning
confidence: 99%
“…, 2021 ). However, abnormal regulation of TG is often correlated with pathophysiological conditions, including neurodegenerative diseases ( Wilhelmus et al ., 2014 ), autoimmune conditions, such as coeliac disease ( Paolella et al ., 2022 ), and cancer ( Lee et al ., 2018 ). These pathological conditions are all associated with elevated TG activity; thus, cells modulate rate-limiting levels of catalytically active TG by maintaining the full-length inactive zymogen.…”
Section: Introductionmentioning
confidence: 99%